Plant Name: Fraxinus szaboana
Taxonomic Information:
Plant ID: NPO9661
Plant Latin Name: Fraxinus szaboana
Taxonomy Genus: Fraxinus
Taxonomy Family: Oleaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| ADRA2C; ADRA2A; | |
| PTPN1; | |
| GAA; ACHE; | |
| TDP1; HKDC1; HPGD; AKR1B1; GFER; HSD17B10; ALOX15; AKR1B10; ALDH1A1; USP2; POLB; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA13; CA7; CA3; CA14; CA5B; CA5A; CA6; | |
| CASP1; CASP7; | |
| MMP9; MMP1; MMP2; | |
| HIF1A; NFKB1; | |
| LMNA; MAPT; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.990E-10 | 1.186E-06 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.229E-27 | 2.676E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.230E-06 | 2.697E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 9.845E-06 | 7.499E-03 | AKR1B1, ALOX15, CA2, CA9, HIF1A, LMNA, MAPK1, MAPT, MMP9, NFKB1, POLB, PTPN1, TDP1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 8.399E-03 | CA2, CA7 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.329E-05 | 8.399E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.350E-05 | 8.399E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A2, GAA, GFER, HPGD, HSD17B10, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.317E-05 | 8.399E-03 | ADRA2A, ADRA2C |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.215E-05 | 8.399E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.626E-21 | 7.214E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.380E-19 | 6.010E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.438E-05 | 1.823E-02 | ADRA2A, CA2, CA9, HPGD, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 6.558E-05 | 2.380E-02 | CA1, CA2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.579E-27 | 1.122E-24 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14, CA13 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.457E-06 | 7.187E-05 | MMP1, MMP2, MAPK1, MMP9 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 4.007E-07 | 2.965E-05 | AKR1B10, GAA, HKDC1, AKR1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.663E-05 | 6.152E-04 | CASP7, CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.471E-04 | 2.420E-03 | MMP1, MMP2, MAPK1, HIF1A, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 5.803E-05 | 1.227E-03 | HKDC1, MAPK1, HIF1A, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.499E-05 | 1.387E-03 | CASP7, MAPK1, MMP9, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.905E-04 | 2.621E-03 | CASP7, LMNA, MAPK1, NFKB1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 3.806E-05 | 1.007E-03 | AKR1B10, HKDC1, AKR1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.948E-04 | 2.621E-03 | CASP7, CASP1, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 3.818E-04 | 4.036E-03 | CASP7, MAPK1, MAPT, HSD17B10 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.532E-04 | 6.771E-03 | AKR1B10, GAA, HKDC1, CYP1A2, ALOX15, ALDH1A1, AKR1B1, HSD17B10, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.497E-04 | 3.981E-03 | HKDC1, MAPK1, HIF1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.167E-04 | 2.672E-03 | CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.777E-04 | 6.771E-03 | MMP2, MAPK1, HIF1A, MMP9 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.159E-03 | 9.029E-03 | MMP2, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.094E-03 | 8.996E-03 | MMP2, MAPK1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 7.272E-04 | 6.771E-03 | CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.084E-05 | 1.007E-03 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; MMP9; MMP2; CA9; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; CA9; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
